- ISIN
- US07373V1052
- CUSIP
- 07373V105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Feb 6, 2020
Highlights
- Market Cap
- $2.63B
- Enterprise Value
- $2.50B
- EPS (TTM)
- -$0.63
- Total Revenue (TTM)
- $132.27M
- Gross Profit (TTM)
- -$84.92M
- EBITDA (TTM)
- -$68.39M
- Year Range
- $15.60 - $38.26
- Target Price
- $40.83
- ROA (TTM)
- -4.39%
- ROE (TTM)
- -5.59%
- Avg. Volume (1M)
- 2M
- Avg. Volume Value (1M)
- $71.79M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BEAM Performance Chart
Beam Therapeutics Inc. (BEAM) is down 7.9% since the beginning of the year. At $26 per share, BEAM is trading 33.3% below its 52-week high of $38. Investors who bought $1,000 worth of BEAM shares 5 years ago would now be looking at an investment worth $277.
Loading charts...
Compare this symbol against anything
Returns By Period
Beam Therapeutics Inc. (BEAM) has returned -7.94% so far this year and 35.53% over the past 12 months.
Beam Therapeutics Inc.
- 1D
- -3.66%
- 1M
- -26.65%
- 6M
- -7.60%
- YTD
- -7.94%
- 1Y
- 35.53%
- 3Y*
- -3.63%
- 5Y*
- -22.62%
- 10Y*
- —
- ALL TIME*
- 0.95%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
BEAM Monthly Returns History
Based on dividend-adjusted daily data since Feb 6, 2020, BEAM's average daily return is +0.13%, while the average monthly return is +2.54%. At this rate, an investment would double in approximately 2.3 years.
Historically, 50% of months were positive and 50% were negative. The best month was Jun 2021 with a return of +64.5%, while the worst month was Apr 2024 at -35.8%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 3 months.
On a daily basis, BEAM closed higher 50% of trading days. The best single day was Feb 27, 2024 with a return of +25.9%, while the worst single day was Mar 16, 2020 at -23.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.36% | 3.04% | -16.27% | 27.28% | 8.57% | 4.22% | -25.64% | -7.94% | |||||
| 2025 | 4.52% | 1.62% | -25.85% | 2.05% | -20.57% | 7.45% | 15.87% | -17.00% | 48.35% | 3.05% | 1.28% | 9.44% | 11.77% |
| 2024 | -10.36% | 61.84% | -16.33% | -35.77% | 12.25% | -1.64% | 35.04% | -15.68% | -8.17% | -10.57% | 24.92% | -9.39% | -8.89% |
| 2023 | 11.10% | -7.39% | -23.91% | 0.29% | 3.87% | 0.09% | -3.32% | -24.91% | 3.75% | -12.10% | 32.83% | -3.06% | -30.40% |
| 2022 | -13.15% | 13.21% | -26.87% | -34.50% | -6.26% | 10.03% | 62.70% | -13.31% | -12.75% | -7.51% | 4.83% | -15.33% | -50.92% |
| 2021 | 18.12% | -7.57% | -10.20% | 2.45% | -4.60% | 64.53% | -28.52% | 20.57% | -21.56% | 2.02% | -10.84% | 0.68% | -2.39% |
Benchmark Metrics
Beam Therapeutics Inc. has an annualized alpha of 11.25%, beta of 1.53, and R2 of 0.15 versus S&P 500 Index. Calculated based on daily prices since February 06, 2020.
- This stock participated in 169.09% of S&P 500 Index downside but only 147.11% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.15 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 11.25%
- Beta
- 1.53
- R²
- 0.15
- Upside Capture
- 147.11%
- Downside Capture
- 169.09%
Return for Risk
Risk / Return Rank
BEAM ranks 61 for risk / return — above 61% of stocks peers on PortfoliosLab. Its historical combined result is above most peers.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Beam Therapeutics Inc. (BEAM) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BEAM | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.02 | ||
| Sortino ratioReturn per unit of downside risk | -0.78 | ||
| Omega ratioGain probability vs. loss probability | 1.13 | 1.25 | -0.12 |
| Calmar ratioReturn relative to maximum drawdown | 0.78 | 2.00 | -1.23 |
| Martin ratioReturn relative to average drawdown | 1.64 | 8.49 | -6.85 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Beam Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Beam Therapeutics Inc. was 89.12%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Beam Therapeutics Inc. drawdown is 80.90%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-89.12%Apr 2025 | 3y 9mo | — | 5y 1moJul 2021 - now | 2025 selloff2025 |
-54.42%Mar 2020 | 1mo 1d | 3mo 22d | 4mo 23dFeb 2020 - Jul 2020 | COVID crash2020 |
-46.90%May 2021 | 3mo | 1mo 21d | 4mo 21dFeb 2021 - Jun 2021 | — |
-37.83%Aug 2020 | 24d | 2mo 13d | 3mo 7dJul 2020 - Oct 2020 | — |
-21.88%Feb 2020 | 1d | 5d | 5dFeb 2020 - Feb 2020 | COVID crash2020 |
Drawdown Indicators
| BEAM | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.12% | -56.78% | -32.34% |
Max Drawdown (1Y)Largest decline over 1 year | -38.15% | -9.10% | -29.05% |
Max Drawdown (3Y)Largest decline over 3 years | -67.74% | -18.90% | -48.84% |
Max Drawdown (5Y)Largest decline over 5 years | -87.25% | -25.43% | -61.82% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -80.90% | -1.58% | -79.32% |
Average DrawdownAverage peak-to-trough decline | -60.22% | -10.70% | -49.52% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.14% | 2.14% | +16.00% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Beam Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Beam Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BEAM relative to other companies in the Biotechnology industry. Currently, BEAM has a P/S ratio of 20.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BEAM in comparison with other companies in the Biotechnology industry. Currently, BEAM has a P/B value of 2.3. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BEAM
Add Beam Therapeutics Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BEAM